The mitral valve poses anatomic challenges to transcatheter treatment that the aortic valve doesn’t. Here’s a glimpse into six ongoing studies designed to overcome them.
In this Q&A, Cleveland Clinic experts explore how to weigh patient age when deciding between surgical and transcathether AVR and what matters most to procedure choice for treating a degenerated aortic bioprosthesis.
Aortic valve replacement options have never been more plentiful, but that means lots of nuanced decision-making. Leaders of Cleveland Clinic’s Aortic Valve Center share their thought processes in this Q&A.
A Cleveland Clinic interventional cardiologist puts the SURTAVI trial in context and speaks to what’s needed to help intermediate-risk patients make the best choice between two good AVR options.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Cleveland Clinic recommends routine CT scanning of the pulmonary veins three to four months after pulmonary vein isolation. This case study of a 25-year-old patient illustrates why.
There’s no end in sight to the past decade of progress in transcatheter aortic valve replacement (TAVR). But experts say the coming years may prove to be the decade of TMVR, or transcatheter mitral valve replacement.
For symptoms of heart failure or hemolytic anemia in a patient with a prosthetic heart valve, think paravalvular leak. Then consider a percutaneous approach for less-invasive repair.
This newly approved percutaneous therapy offers a minimally invasive option for mitral regurgitation patients at high risk from surgery. Ongoing studies aim to better define just which patients benefit.